The 5 Best Performing Stocks of 2019

We’re halfway through 2019—yes, really. With the Fourth of July holiday here, it’s time to take note of how stocks have done so far.

Here’s a look at the five companies with the best-performing stocks in the S&P 500 this year through the first half, which ended last week. The benchmark index gained 16.5% through June, while the Dow Jones Industrial Average rose 13.9% and the Nasdaq Composite added 20.1%. Check out the five worst stocks so far this year here.

Coty
Coty stock (COTY) was up a whopping 89.2% through June. The parent company of Covergirl soared largely on a February offer from German conglomerate Jab Holding to boost its stake in the stock. A second spike came in May. But Coty stock fell 13.5% on the first day of the second half, when the company announced a $3 billion write-down on the multi-billion-dollar beauty business it acquired three years ago from Procter & Gamble , as well as a turnaround plan that failed to impress investors.

Xerox
Xerox stock (XRX) is up 75.5% through June, thanks to a huge surge after its first-quarter earnings report. Xerox has benefitted from better management of its software offerings under the new leadership of CEO John Visentin. It’s been one of a handful software and chip stocks to soar during this year’s market rally.

Read the full article at Barron's.

Don’t Stop Here

More To Explore

Market Brief: AI Risks and Fed Minutes Incoming

Market Snapshot Market Pulse: U.S. stocks edged sideways, buoyed by fresh AI chatter that kept tech afloat while industrial sectors shrugged off supply-chain jitters. Bond

AARD: 56% Drop Sparks Urgent Investor Scrutiny!

Overview: Aardvark Therapeutics, Inc. (Nasdaq: AARD) is a clinical-stage biotech focused on therapies for metabolic diseases and Prader-Willi Syndrome (PWS) – a rare genetic disorder

Gene-Editing Goldrush Meets AI and ETF Plays

Opening Recap Market Pulse: Gene-editing fervor rippled through biotech circles after a Mordor Intelligence report flagged double-digit growth in cell line development through 2031. Down